Bill Gadless

Founding Partner, emagineHealth: the Digital-First, AI-Powered Marketing Agency for Healthcare, Life Sciences, Medical Device, CDMO and CRO brands.

[Bill Gadless @BillGadless]

𝗪𝗵𝘆 𝗮𝗿𝗲 𝘄𝗲 𝘀𝗼 𝘀𝗰𝗮𝗿𝗲𝗱 𝘁𝗼 𝘀𝗼𝘂𝗻𝗱 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝘁?
Most science founders I meet have a weird relationship with marketing.

They act like "selling" is a dirty word. They worry that if they speak too loudly, they’ll look like they’re hyping vaporware. They think "serious" science has to be dry, dense, and boring.

𝗦𝗼 𝘁𝗵𝗲𝘆 𝗵𝗶𝗱𝗲.

They hide behind 40-slide decks cluttered with data. They hide behind acronyms. They whisper their value prop because they’re terrified of being seen as "commercial."

Here’s the reality check:
Quiet science doesn’t get funded. It doesn’t get partnered. And it definitely doesn’t get to the patient.

If you’ve truly got the goods, being "modest" isn’t a virtue. It’s a liability.

The disease you are fighting isn't being polite. It isn't waiting for investors to read between the lines or for the market to "eventually" figure out why you matter.

𝗦𝘁𝗼𝗽 𝗮𝗽𝗼𝗹𝗼𝗴𝗶𝘇𝗶𝗻𝗴 𝗳𝗼𝗿 𝘀𝗲𝗹𝗹𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝘃𝗶𝘀𝗶𝗼𝗻.
If the science is real, you have a duty to make sure the world hears it.

𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗲 𝗵𝗮𝗿𝗱𝗲𝗿. 𝗧𝗲𝗹𝗹 𝘆𝗼𝘂𝗿 𝘀𝘁𝗼𝗿𝘆 𝗹𝗼𝘂𝗱𝗲𝗿. 𝗢𝗵, 𝗮𝗻𝗱 𝗙 𝗰𝗮𝗻𝗰𝗲𝗿.

[Bill Gadless @BillGadless]

𝗪𝗵𝘆 𝗺𝘆 𝗰𝗮𝗻𝗰𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝗮𝘃𝗲 𝗹𝗶𝘃𝗲𝘀.
I was diagnosed with stage 3 esophageal cancer in October 2024.
Yes, this is personal.
But this series isn’t about my story.
It’s about what became painfully clear the moment I became a patient.

𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗲𝘅𝗶𝘀𝘁 𝘁𝗵𝗮𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗰𝗮𝗻’𝘁 𝗳𝗶𝗻𝗱.
Trials struggle to enroll while people search for options.
Life-saving innovation sits in pipelines, decks, and internal conversations - moving slower than disease ever will.

𝗙𝗿𝗼𝗺 𝘁𝗵𝗲 ����𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗯𝗲𝗱, 𝘂𝗿𝗴𝗲𝗻𝗰𝘆 𝗳𝗲𝗲𝗹𝘀 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁.
Language matters more.
Silence gets dangerous.

I’m launching this new series - Why My Cancer Will Save Lives - to talk about that gap.

And why better storytelling closes it.
Lives don’t move at corporate speed.

[Bill Gadless @BillGadless]

“𝗧𝗵𝗮𝘁’𝘀 𝗺𝘆 𝘀𝗼𝗻,” 𝘀𝗵𝗲 𝘀𝗮𝗶𝗱.
Her child’s heart is still beating - inside a 14-year-old boy who’s alive because of it. 💔❤️

[Bill Gadless @BillGadless]

#𝗝𝗣𝗠𝟮𝟲: 𝗘𝗹�� 𝗟𝗶𝗹𝗹𝘆 𝗮𝗻𝗱 𝗡𝘃𝗶𝗱𝗶𝗮 𝗷𝘂𝘀𝘁 𝗹𝗼𝗰𝗸𝗲𝗱 𝗶𝗻 𝗮 $𝟭𝗕 𝗔𝗜 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 - 𝗮𝗻𝗱 𝗶𝘁 𝘀𝗮𝘆𝘀 𝗮 𝗹𝗼𝘁 𝗮𝗯𝗼𝘂𝘁 𝘄𝗵𝗲𝗿𝗲 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗶𝘀 𝗵𝗲𝗮𝗱𝗲𝗱.
This wasn’t a fluffy “AI will change everything” moment on a JPM stage. It was two CEOs admitting how fast the ground has shifted.

Jensen Huang talking about AI accelerating a million-fold.
David Ricks saying speed - not ideas - is now the real competitive edge.

Lilly is doing more than dabbling. Between Nvidia, Benchling, Chai, Schrödinger, OpenAI … this is a full-stack AI strategy. Data. Models. Compute. Talent.

The signal is clear: future blockbusters won’t come from better PowerPoints.

They’ll come from companies that build the machine to discover faster than everyone else.

#ai #drugdevelopment #tech #bigtech #pharma #pharmaceuticals #biotech #biopharma #nvidia #elililly #lilly #drugdiscovery

[Bill Gadless @BillGadless]

The world doesn’t produce enough Tim Tebows.

[Bill Gadless @BillGadless]

It’s been a long road of chemo and a transplant, but today made it all worth it: He is officially heading home cancer-free. ❤️

[Bill Gadless @BillGadless]

𝗧𝗵𝗲 𝗺𝗮𝗻 𝘀𝗼 𝗺𝗮𝗻𝘆 𝗼𝗳 𝘂𝘀 𝗮𝘀𝗽𝗶𝗿𝗲 𝘁𝗼 𝗯𝗲.
Today, we celebrate Christian Nolen’s 13th anniversary at emagine.

Christian’s journey is the perfect example of growth:
• Started as a Web Developer
• Promoted to Technical Director
• Now runs the show as EVP of Operations

Overseeing operations at the volume we handle is no small feat. It requires precision, but more importantly, it requires composure.

Christian has an uncanny ability to stay cool and level-headed regardless of the chaos around him.

He is a brilliant executive, a devoted husband, a proud father of two boys, and someone I’m honored to call a friend.

Ask anyone on his team, and they will tell you the same thing: We can all learn from Christian.

Happy 13th, Christian. Thank you for everything you do.

[Bill Gadless @BillGadless]

𝗜 𝘁𝗵𝗼𝘂𝗴𝗵𝘁 𝗜 𝗸𝗻𝗲𝘄 𝘁𝗵𝗲 "𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗝𝗼𝘂𝗿𝗻𝗲𝘆." 𝗧𝗵𝗲𝗻 𝗜 𝗵𝗮𝗱 𝘁𝗼 𝘄𝗮𝗹𝗸 𝗶𝘁.
For years, I treated the patient journey like a funnel - a slide in a deck, a conversion strategy.

Then came my diagnosis.
Suddenly, the funnel wasn’t abstract. It was 3 AM anxiety. It was decoding complex jargon while terrified. It was the desperate wait for a solution.

Cancer didn't just change my life; it completely rewired how I view my job.

Here is the reality:
- Time is the only currency. Delays don't just lose revenue; they cost families time.

- Marketing is access. If a patient can’t find, afford, or understand the science, it doesn't exist.

- Empathy > Buzzwords. Patients don't want "innovative solutions." They want to know if they’ll see their kid graduate.

This experience lit a fire under my creativity. I’m not just chasing KPIs anymore. I’m fueled by a need to get science to patients faster and more economically.

My creativity is now a survival mechanism - for me, and for the millions walking this path.

Let’s stop marketing at patients and start fighting for them.

[Bill Gadless @BillGadless]

𝗬𝗼𝘂𝗿 𝗽𝗶𝘁𝗰𝗵 𝗱𝗲𝗰𝗸 𝗳𝗼𝗿 𝗝𝗣𝗠 𝟮𝟬𝟮𝟲 𝗶𝘀𝗻’𝘁 𝗮 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗳𝗮𝗶𝗿 𝗽𝗼𝘀𝘁𝗲𝗿 - 𝗶𝘁’𝘀 𝗮 𝗰𝗹𝗲𝗮𝗿, 𝗰𝗼𝗻𝗰𝗶𝘀𝗲 𝗲𝘅𝗶𝘁 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆.
Everyone has good data.
Everyone has a breakthrough.

If you're heading to San Francisco, you need to remember the investors' core mission: return on capital.

They don't have time to wade through your 80-slide deep dive.

Your 30-minute speed date needs to hit the essentials: clear regulatory path, commercial viability, and a team that can execute.

Show them how the science translates directly into dollars and impact. That's how you get funded.

[Bill Gadless @BillGadless]

Can’t wait to get back on camera.
The energy in life sciences right now is unreal.
After a couple of quiet, even lame years, the sector finally feels alive again - innovation, funding, new stories worth shouting about.

And I’m itching to be part of that conversation - through high-energy, straight-talk video content like I used to do.

But here’s the truth: I’m still recovering from surgery. My energy’s limited, my strength’s not all there, and yeah… I’m not feeling great about how I look on camera right now.

Still - the ideas are flowing. The fire’s back.
And the moment I’ve got the energy to match it, I’m hitting record. ⏺️

I can’t wait to talk with all of you again - for real, face-to-face (well, screen-to-screen).

#biotech #pharma #LifeSciences #marketing #cdmo

[Bill Gadless @BillGadless]

@thermofisher dropped a quiet but important signal for biotech and pharma.
They beat expectations - $11.1B in sales, up 5%, and $5.79 a share in earnings vs. Wall Street’s $5.50.
The life sciences division did the heavy lifting, jumping to $2.59B from $2.39B last year.

Here’s what’s interesting: analysts say pharma’s finally loosening the purse strings now that tariff worries are fading.

That means R&D is picking up again - and Thermo’s numbers are the first proof.

If this trend sticks, it could be the start of a real rebound across life science.

#thermofisher
#LifeSciences
#biotech
#pharma
#economy

[Hemostasis Today @HemostasisToday]

The Industry Isn’t Abandoning Cell Therapy, It is Returning to What Works - @Ori_JCFoster
@TakedaPharma | @novonordisk | @GalapagosGlobal
@LeeBuckler4 | @BillGadless

https://t.co/n1uaa1D81s

#Galapagos #Health #Hematology #Hemostasis #HemostasisToday #Medicine #NovoNordisk #MedX #MedEd #OriBiotech #Takeda

[Bill Gadless @BillGadless]

Eli Lilly just did what no one thought possible - it beat Keytruda.
Mounjaro + Zepbound (tirzepatide) pulled in $10.1B last quarter, topping Merck’s $8.1B from Keytruda. Total Q3 revenue? Up 54% to $17.6B - even with price cuts.

When a weight-loss drug overtakes the world’s #1 cancer therapy, the message is clear:
The next pharma arms race isn’t in oncology.
It’s in metabolism.

#EliLilly #GLP1 #Mounjaro #Zepbound #PharmaNews #MetabolicHealth #Biotech

[Bill Gadless @BillGadless]

Novartis just threw down $12B to go after muscle.
They’re buying Avidity Biosciences - one of the few biotechs actually figuring out how to get RNA drugs into muscle instead of just the liver.

It’s a big move, but it makes sense. Avidity’s chasing treatments for Duchenne and myotonic dystrophy - two brutal diseases with almost no real options.

If their data holds up next year, this could be a turning point.

[Bill Gadless @BillGadless]

@Novartis just dropped $12B to go after muscle.

They’re buying @aviditybio — one of the few biotechs figuring out how to get RNA drugs into muscle, not just the liver.

It’s bold, but smart. Avidity’s chasing treatments for Duchenne and myotonic dystrophy — diseases with almost no real options.

If their data holds up next year, this could be a real turning point.

#biotech
#pharma

[Bill Gadless @BillGadless]

@Novartis just dropped $12B to go after muscle.
They’re buying @aviditybio — one of the few biotechs figuring out how to get RNA drugs into muscle, not just the liver.

It’s bold, but smart. Avidity’s chasing treatments for Duchenne and myotonic dystrophy — diseases with almost no real options.

If their data holds up next year, this could be a real turning point.

#biotech
#pharma